Evaluation of drug –drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)

ConclusionAlthough concomitantly administered strong CYP3A4 inhibitors increased midostaurin exposure 1.44-fold, no clinically relevant differences in safety were noted. Midostaurin dose adjustment is not necessary with concomitant strong CYP3A4 inhibitors in patients withFLT3-mutated AML; however, caution is advised, and patients should be closely monitored.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research